Related Symbol
avatar
@Zalotie 1 month ago

IOVA up 6% after Goldman sets $15 price target

IOVA up 6% after Goldman sets $15 price target

Goldman Sachs resumed coverage on Iovance Biotherapeutics with a buy rating and a $15 price target. The stock gained about 6% on Thursday. The analyst pointed to strong Q2 numbers for their melanoma drug Amtagvi, which generated $91 million in sales. They noted that operational roadblocks are clearing up and survey data shows solid demand for the treatment.
post thumbnail
@TallDrive706 1 month ago

Amtagvi’s $91M Q2 sales are encouraging, but the key test is whether cleared operational hurdles translate into sustained demand and broader commercial growth.

@Nathan956 1 month ago

I am curious to see if Iovance Biotherapeutics can keep this momentum going through the rest of the year.